Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.
CD28
Costimulation blockade
Dermal fibrosis
ICOS
Pulmonary fibrosis
Pulmonary hypertension
Systemic sclerosis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
05 01 2022
05 01 2022
Historique:
received:
21
09
2021
accepted:
20
12
2021
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Uncontrolled immune response with T cell activation has a key role in the pathogenesis of systemic sclerosis (SSc), a disorder that is characterized by generalized fibrosis affecting particularly the lungs and skin. Costimulatory molecules are key players during immune activation, and recent evidence supports a role of CD28 and ICOS in the development of fibrosis. We herein investigated the efficacy of acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, in two complementary SSc-related mouse models recapitulating skin fibrosis, interstitial lung disease, and pulmonary hypertension. Expression of circulating soluble ICOS and skin-expressed ICOS was investigated in SSc patients. Thereafter, acazicolcept was evaluated in the hypochlorous acid (HOCL)-induced dermal fibrosis mouse model and in the Fra-2 transgenic (Tg) mouse model. In each model, mice received 400 μg of acazicolcept or a molar-matched dose of an Fc control protein twice a week for 6 weeks. After 6 weeks, skin and lung were evaluated. ICOS was significantly increased in the sera from SSc patients and in SSc skin biopsies as compared to samples from healthy controls. Similar body weight changes were observed between Fc control and acazicolcept groups in both HOCL and Fra-2 Tg mice suggesting a good tolerance of acazicolcept treatment. In mice challenged with HOCL, acazicolcept induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages. In the Fra-2 Tg mouse model, acazicolcept treatment reduced lung collagen content, fibrillar collagen, histological fibrosis score, and right ventricular systolic pressure (RVSP). A reduction in frequency of CD4+ and T effector memory cells and an increase in the percentage of CD4+ T naïve cells in spleen and lung of acazicolcept-treated Fra-2 Tg mice was observed as compared to Fc control-treated Fra-2 Tg mice. Moreover, acazicolcept reduced CD69 and PD-1 expression on CD4+ T cells from the spleen and the lung. Target engagement by acazicolcept was demonstrated by blockade of CD28 and ICOS detection by flow cytometry in treated mice. Our results confirm the importance of costimulatory molecules in inflammatory-driven fibrosis. Our data highlight a key role of ICOS and CD28 in SSc. Using complementary models, we demonstrated that dual ICOS/CD28 blockade by acazicolcept decreased dermal and pulmonary fibrosis and alleviated pulmonary hypertension. These results pave the way for subsequent research on ICOS/CD28-targeted therapies.
Sections du résumé
BACKGROUND
Uncontrolled immune response with T cell activation has a key role in the pathogenesis of systemic sclerosis (SSc), a disorder that is characterized by generalized fibrosis affecting particularly the lungs and skin. Costimulatory molecules are key players during immune activation, and recent evidence supports a role of CD28 and ICOS in the development of fibrosis. We herein investigated the efficacy of acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, in two complementary SSc-related mouse models recapitulating skin fibrosis, interstitial lung disease, and pulmonary hypertension.
METHODS
Expression of circulating soluble ICOS and skin-expressed ICOS was investigated in SSc patients. Thereafter, acazicolcept was evaluated in the hypochlorous acid (HOCL)-induced dermal fibrosis mouse model and in the Fra-2 transgenic (Tg) mouse model. In each model, mice received 400 μg of acazicolcept or a molar-matched dose of an Fc control protein twice a week for 6 weeks. After 6 weeks, skin and lung were evaluated.
RESULTS
ICOS was significantly increased in the sera from SSc patients and in SSc skin biopsies as compared to samples from healthy controls. Similar body weight changes were observed between Fc control and acazicolcept groups in both HOCL and Fra-2 Tg mice suggesting a good tolerance of acazicolcept treatment. In mice challenged with HOCL, acazicolcept induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages. In the Fra-2 Tg mouse model, acazicolcept treatment reduced lung collagen content, fibrillar collagen, histological fibrosis score, and right ventricular systolic pressure (RVSP). A reduction in frequency of CD4+ and T effector memory cells and an increase in the percentage of CD4+ T naïve cells in spleen and lung of acazicolcept-treated Fra-2 Tg mice was observed as compared to Fc control-treated Fra-2 Tg mice. Moreover, acazicolcept reduced CD69 and PD-1 expression on CD4+ T cells from the spleen and the lung. Target engagement by acazicolcept was demonstrated by blockade of CD28 and ICOS detection by flow cytometry in treated mice.
CONCLUSIONS
Our results confirm the importance of costimulatory molecules in inflammatory-driven fibrosis. Our data highlight a key role of ICOS and CD28 in SSc. Using complementary models, we demonstrated that dual ICOS/CD28 blockade by acazicolcept decreased dermal and pulmonary fibrosis and alleviated pulmonary hypertension. These results pave the way for subsequent research on ICOS/CD28-targeted therapies.
Identifiants
pubmed: 34986869
doi: 10.1186/s13075-021-02709-2
pii: 10.1186/s13075-021-02709-2
pmc: PMC8728910
doi:
Substances chimiques
CD28 Antigens
0
ICOS protein, human
0
Icos protein, mouse
0
Inducible T-Cell Co-Stimulator Protein
0
Single-Chain Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Informations de copyright
© 2021. The Author(s).
Références
Nat Rev Immunol. 2003 Jul;3(7):544-56
pubmed: 12876557
Gastroenterology. 2004 Mar;126(3):829-39
pubmed: 14988837
Arthritis Rheumatol. 2020 Jan;72(1):125-136
pubmed: 31342624
Ann Rheum Dis. 2020 Dec;79(12):1588-1599
pubmed: 32963045
Clin Immunol. 2013 May;147(2):95-104
pubmed: 23578551
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10525-30
pubmed: 18641127
Lupus. 2018 Jan;27(1):143-149
pubmed: 28764616
Clin Exp Immunol. 2016 Mar;183(3):405-18
pubmed: 26540618
Immunity. 2016 May 17;44(5):973-88
pubmed: 27192564
Arthritis Res Ther. 2018 Aug 29;20(1):197
pubmed: 30157927
J Immunol. 2017 Oct 1;199(7):2305-2315
pubmed: 28814605
J Clin Pathol. 1988 Apr;41(4):467-70
pubmed: 3366935
Arthritis Rheumatol. 2018 May;70(5):774-784
pubmed: 29361207
Clin Exp Immunol. 2013 Nov;174(2):212-20
pubmed: 23786438
Open Rheumatol J. 2012;6:87-95
pubmed: 22802906
Ann Rheum Dis. 2019 Apr;78(4):539-550
pubmed: 30760472
Ann Rheum Dis. 2020 Dec;79(12):1600-1607
pubmed: 32963047
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Front Immunol. 2016 Aug 10;7:304
pubmed: 27559335
Eur J Haematol. 1996 Mar;56(3):119-23
pubmed: 8598229
J Rheumatol. 2011 Oct;38(10):2105-11
pubmed: 21807779
J Immunol. 2009 May 1;182(9):5855-64
pubmed: 19380834
Rheumatology (Oxford). 2013 Feb;52(2):242-51
pubmed: 23024058
J Exp Med. 2021 Jun 7;218(6):
pubmed: 33881452
J Immunol Res. 2016;2016:1058165
pubmed: 27446964
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3901-10
pubmed: 27298374
Circ Res. 2014 Jun 20;115(1):165-75
pubmed: 24951765
Eur J Immunol. 2017 Aug;47(8):1368-1376
pubmed: 28631301
Sci Transl Med. 2018 Mar 7;10(431):
pubmed: 29514998
J Immunol. 2009 Feb 1;182(3):1421-8
pubmed: 19155489
Arthritis Rheumatol. 2015 Apr;67(4):988-99
pubmed: 25581113
J Immunol. 2003 Sep 15;171(6):2848-54
pubmed: 12960306
Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):583-93
pubmed: 21978690
Cell Signal. 2019 Dec;64:109408
pubmed: 31473307
Am J Transplant. 2014 Nov;14(11):2460-6
pubmed: 25323029
Ann Rheum Dis. 2012 Aug;71(8):1382-7
pubmed: 22523431
J Clin Invest. 1996 May 1;97(9):2027-37
pubmed: 8621791
Arthritis Rheum. 2010 Jun;62(6):1723-32
pubmed: 20191584
Nature. 1999 Jan 21;397(6716):263-6
pubmed: 9930702
J Immunol. 2001 Apr 15;166(8):4943-8
pubmed: 11290772
Arch Dermatol Res. 2013 Jan;305(1):17-23
pubmed: 23053221
Clin Transl Sci. 2021 Jul;14(4):1314-1326
pubmed: 33503289
Arthritis Rheum. 2010 Jan;62(1):234-44
pubmed: 20039395
Rheumatology (Oxford). 2005 Oct;44(10):1245-54
pubmed: 15987711
Semin Immunopathol. 2015 Sep;37(5):519-28
pubmed: 26152639
Ann Rheum Dis. 2017 Nov;76(11):1931-1940
pubmed: 28801346
Front Immunol. 2018 Dec 18;9:2998
pubmed: 30619351
Ann Rheum Dis. 2016 Dec;75(12):2142-2149
pubmed: 26912566
Ann Rheum Dis. 2010 Aug;69(8):1495-501
pubmed: 20498202
Eur J Immunol. 1996 Oct;26(10):2320-8
pubmed: 8898940
Ann Rheum Dis. 2017 Nov;76(11):1897-1905
pubmed: 28835464
PLoS One. 2013;8(3):e57820
pubmed: 23469245
J Hepatol. 2010 Mar;52(3):398-406
pubmed: 20149472
Nat Immunol. 2001 Jul;2(7):597-604
pubmed: 11429543
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 33028709
J Pathol. 1992 Mar;166(3):255-63
pubmed: 1517881
Cell Rep. 2020 Jun 30;31(13):107826
pubmed: 32610127
J Clin Invest. 2020 May 1;130(5):2451-2464
pubmed: 31990684
Arthritis Rheumatol. 2018 Jul;70(7):1071-1076
pubmed: 29513931
J Immunol. 2021 Mar 1;206(5):1102-1113
pubmed: 33495237